OptiPharm Co

OptiPharm Co EBIT per Employee

The EBIT per Employee of OptiPharm Co (153710.KQ) as of Nov 14, 2026 is -33.13 M KRW. In the previous year, EBIT per Employee was -35.55 M KRW — a change of -6.81% (higher).

EBIT per Employee

-33.13 MKRW

YoY

-6.81%

Last updated:

EBIT per Employee of OptiPharm Co is 2024 -33.13 M KRW. EBIT per Employee of OptiPharm Co was 2023 -35.55 M KRW. It decreases by -6.81% higher compared to the previous year.

The OptiPharm Co EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2017
-22.05 M KRW
Jan 1, 2018
-9.41 M KRW
Jan 1, 2019
-16.09 M KRW
Jan 1, 2020
-46.67 M KRW
Jan 1, 2021
-60.87 M KRW
Jan 1, 2022
-45.64 M KRW
Jan 1, 2023
-35.55 M KRW
Jan 1, 2024
-33.13 M KRW
The OptiPharm Co EBIT per Employee history
YEAREBIT per EmployeeYoY
-33.13 MKRW-6.81%
-35.55 MKRW-22.10%
-45.64 MKRW-25.03%
-60.87 MKRW+30.44%
-46.67 MKRW+189.96%
-16.09 MKRW+71.02%
-9.41 MKRW-57.31%
-22.05 MKRW-8,231.55%
271,113.24KRW-101.07%
-25.36 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiPharm Co Stock analysis

What does OptiPharm Co do? OptiPharm Co Ltd generates revenue through its Sale Business segment, which provides livestock disease appraisal services, distributes animal drugs, and manufactures and sells feed additives. The New Business segment develops heterologous organisms, VLP vaccines, and human diagnostic kits, including heterologous skin, xenogeneic islets, and xenogeneic corneal products, as well as VLP-based animal combined vaccines and HPV vaccines for humans. Human diagnostic kits target breast and cervical cancer reagents. Products are distributed domestically and internationally, serving both local and overseas markets. The company's primary customers are domestic and international buyers of pharmaceuticals, livestock health products, and diagnostic solutions. The Sale Business segment caters to agricultural and veterinary sectors, while the New Business segment serves healthcare providers and diagnostic laboratories. Revenue streams include product sales from both segments, with a focus on high-demand medical and animal health solutions. OptiPharm Co Ltd's business model relies on manufacturing and wholesaling pharmaceuticals, with the Sale Business segment emphasizing livestock health services and animal drug distribution, and the New Business segment focusing on innovative medical technologies. The firm's product portfolio spans from feed additives to advanced diagnostic kits, targeting both domestic and global markets for sustainable growth. OptiPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiPharm Co stock

EBIT per Employee of OptiPharm Co is -33.13 M KRW in 2024.

EBIT per Employee of OptiPharm Co changed from -35.55 M KRW to -33.13 M KRW, representing a -6.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee OptiPharm Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's OptiPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — OptiPharm Co

All Key Metrics — OptiPharm Co